{"classes":[{"categories":[{"measurements":[{"comment":"Median and upper limit of overall survival was not estimable due to low number of participants with events.","groupId":"OG000","lowerLimit":"30.85","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"OS was defined as the time from the date of first study drug administration to the date of death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ixazomib 4 mg, capsules, orally on Days 1, 8, and 15 plus lenalidomide 25 mg, capsule, orally, once daily on Days 1 through 21 and dexamethasone 40 mg, tablet, orally on Days 1, 8, 15, and 22 of a 28-day cycle up to 32 cycles.","id":"OG000","title":"Ixazomib 4 mg + Lenalidomide 25 mg + Dexamethasone 40 mg"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants who received at least one dose of study drug during the treatment period. Participants without documentation of death at the time of the analysis were censored at the date when they were last known to be alive.","reportingStatus":"POSTED","timeFrame":"Up to approximately 33 months","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}